Sonoma Pharmaceuticals (SNOA) Net Cash Flow (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Net Cash Flow came in at -$161000.0 in Q1 2026, down 261.0% year-on-year from $100000.0 in Q1 2025, and up 73.21% quarter-over-quarter from -$601000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Net Cash Flow (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$161000.0 for Q1 2026.
- On a quarterly basis, Net Cash Flow fell 261.0% year-over-year to -$161000.0 in Q1 2026; TTM through Mar 2026 was -$3.6 million, a 227.46% decrease from a year earlier, with the FY2026 full-year figure at -$3.6 million, down 227.46% from the prior year.
- Net Cash Flow climbed to -$161000.0 in Q1 2026 per SNOA's latest filing, from -$601000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $1.8 million in Q3 2024 and bottomed at -$2.2 million in Q3 2022.
- The 5-year median for Net Cash Flow is -$367000.0 (2023), against an average of -$392058.8.
- Across the five-year window, Net Cash Flow jumped 496.71% in 2024 and tumbled 675.44% in 2025, its largest moves.
- Year by year, Net Cash Flow stood at -$632000.0 in 2022, then jumped by 133.7% to $213000.0 in 2023, then soared by 496.71% to $1.3 million in 2024, then tumbled by 147.29% to -$601000.0 in 2025, then jumped by 73.21% to -$161000.0 in 2026.
- Per Business Quant, the three latest SNOA Net Cash Flow figures stand at -$161000.0 (Q1 2026), -$601000.0 (Q4 2025), and -$707000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | -277.40 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Sonoma Pharmaceuticals | 1.92 Mn | -479,240.02 | 2.18 Mn | -161,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -161,000.00 |
| Mar 31, 2026 | -161,000.00 |
| Dec 31, 2025 | -601,000.00 |
| Dec 31, 2025 | -601,000.00 |
| Sep 30, 2025 | -707,000.00 |
| Sep 30, 2025 | -707,000.00 |
| Jun 30, 2025 | -2.18 Mn |
| Jun 30, 2025 | -2.18 Mn |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 1.27 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | -281,000.00 |
| Jun 30, 2024 | -281,000.00 |
| Mar 31, 2024 | 792,000.00 |
| Mar 31, 2024 | 792,000.00 |
| Dec 31, 2023 | 213,000.00 |
| Dec 31, 2023 | 213,000.00 |